BOULDER, Colo., June 16, 2025 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Fighting off a nasty headache after your cousin’s wedding? Stomach virus have you feeling fatigued? Gearing up for tomorrow’s half-marathon? Many of us might be tempted to pop into an “IV bar” to seek relief […]
NXGB Looks to ‘Disrupt the Norm’™ with first Acquisition WHEAT RIDGE, Colo. , Nov. 30, 2023 /PRNewswire/ — NxGen Brands, Inc. (OTCMKTS: NXGB) (“NxGen” or the “Company”), (www.nxgenbrands.com) outlines its vision for the recently acquired […]
While some pandemic-related stressors have receded, burnout among physicians and other healthcare professional remains at elevated levels. Studies show relatively high percentages of physicians are cutting back hours or are thinking about leaving the profession, […]
Copyright © 2026 Biotech Networks
